Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pKM2L-phPSA(3) (#RDB05910)

Promoter Bank clone, Human prostate-specific antigen/kallikrein 3 (PSA/KLK3) promoter

Alternative name p1996-8F
Clone info. PCR amplified human prostate-specific antigen/kallikrein 3 (PSA/KLK3) promoter sequence was inserted into a Renilla luciferase reporter vector pKM2L (RDB04026). Cloned fragment: 50854208 to 50854952(NC_000019.10); relatively -707 to +38, where +1 corresponds to 1 nt of NM_001648.2.
Comment PCR cloning, forward primer, 1996 F2: 5' agggcaggtcagcaggcatctctgt 3'; reverse primer, 1996 R2: 5' gacacagctctccgggtgcaggtgg 3' (reference: J. Biol. Chem., 271, 6379-6388, 1996, PMID:8626436) Entire sequence of promoter region has not been confirmed.
Vector backbone pKM2L (RDB04026) (Plasmid)
Size of vector backbone 4.2 kb
Selectable markers Kan^r
Gene/insert name Human prostate-specific antigen/kallikrein 3 (PSA/KLK3) genomic DNA
Depositor|Developer DNA Bank, |
 
Sequence RDB05910z.seq
Remarks, protocol and/or map (pdf) RDB05910.pdf

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution 1. The RECIPIENT agrees to use the BIOLOGICAL RESOURCE only for academic research in the non-profit organization. 2. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 1. 本件リソースは学術研究機関にのみ提供し、学術研究にのみ利用することができる。　2. 謝辞の表明を必要とする。
MTAに書く付加的使用条件：
本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB05910 pKM2L-phPSA(3) DNA solution

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pKM2L-phPSA(3) was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB05910).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB14605_A7B9p1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: M13_-40
Sequence file: RDB14605_A7B9a.seq check
>05910_14605_A7B9_M13(-40)_C03_03_ABI08.ab1
    1 CCGGCCGGGG CCAGCCTTGC ATGCCTGCAG GTCATTTAAA TAGGGATAAC AGGGTAATGA
   61 TTAAGATCTC GAGCTCTAAG CTTCACATAT GCATGCACTA GTGGCAGGGC AGGTCAGCAG
  121 GCATCTCTGT TGCACAGATA GAGTGCACAG GTCTGGAGAA CAAGGAGTGG GGGGTTATTG
  181 GAATTCCACA TTGTTTGCTG CACGTTGGAT TTTGAAATGC TAGGGAACTT TGGGAGACTC
  241 ATATTTCTGG GCTAGAGGAT CTGTGGACCA CAAGATCTTT TTATGATGAC AGTAGCAATG
  301 TATCTGTGGA GCTGGATTCT GGGTTGGGAG TGCAAGGAAA AGAATGTACT AAATGCCAAG
  361 ACATCTATTT CAGGAGCATG AGGAATAAAA GTTCTAGTTT CTGGTCTCAG AGTGGTGCAG
  421 GGATCAGGGA GTCTCACAAT CTCCTGAGTG CTGGTGTCTT AGGGCACACT GGGTCTTGGA
  481 GTGCAAAGGA TCTAGGCACG TGAGGCTTTG TATGAAGAAT CGGGGATCGT ACCCACCCCC
  541 TGTTTCTGTT TCATCCTGGG CGTGTCTCCT CTGCCTTTGT CCCCTAGATG AAGTCTCCAT
  601 GAGCTACAGG GCCTGGTGCA TCCAGGGTGA TCTAGTAATT GCAGAACAGC AAGTGCTAGC
  661 TCTCCCTCCC CTTCCACAGC TCTGGGTGTG GGAGGGGGTT GTCCAGCCTC CAGCAGCATG
  721 GGGAGGGCCT TGGTCAGCCT CTGGGTGCCA GCAGGGCAGG GGCGGAGTCC TGGGGAATGA
  781 AGGTTTTATA GGGCTCCTGG GGGAGGCTCC CCAGCCCCAA GCTTACCACC TGCACCCGGA
  841 GAGCTGTGTC GCCTGTCGAC GCGTAGAATT CACCCGGGTA CTGCAGAAGT TGGTCGTGAG
  901 GCACTGGGGC AGGTAAGTAT CAAGGTTACA AGACAGGTTT TAAGGAGACC AATAGAAAAC
  961 TGGGGCTTTG TCGAGACAGG AGAAGACTCT TTGCGTTCTG ATAAGGCACC TATTGGGTTC
 1021 TTTACTGACA TCACTTGGCC CTTTCTCCTC CACAAGTGTC AACTCCAGGT TCAATACAGG
1081 CTCTAGCCTA GAGTTACTTA ATTAACGGAA C
//
Primer: phRLR2
Sequence file: RDB14605_A7B9b.seq check
>05910_14605_A7B9_phRLR2_D03_04_ABI08.ab1
    1 AATTTCTCTG TCTGGAAAGC CCAGTTTCTA TTGGTCTCCT TAAACCTGTC TTGTAACCTT
   61 GATACTTACC TGCCCAGTGC CTCACGACCA ACTTCTGCAG TACCCGGGTG AATTCTACGC
  121 GTCGACAGGC GACACAGCTC TCCGGGTGCA GGTGGTAAGC TTGGGGCTGG GGAGCCTCCC
  181 CCAGGAGCCC TATAAAACCT TCATTCCCCA GGACTCCGCC CCTGCCCTGC TGGCACCCAG
  241 AGGCTGACCA AGGCCCTCCC CATGCTGCTG GAGGCTGGAC AACCCCCTCC CACACCCAGA
  301 GCTGTGGAAG GGGAGGGAGA GCTAGCACTT GCTGTTCTGC AATTACTAGA TCACCCTGGA
  361 TGCACCAGGC CCTGTAGCTC ATGGAGACTT CATCTAGGGG ACAAAGGCAG AGGAGACACG
  421 CCCAGGATGA AACAGAAACA GGGGGTGGGT ACGATCCCCG ATTCTTCATA CAAAGCCTCA
  481 CGTGCCTAGA TCCTTTGCAC TCCAAGACCC AGTGTGCCCT AAGACACCAG CACTCAGGAG
  541 ATTGTGAGAC TCCCTGATCC CTGCACCACT CTGAGACCAG AAACTAGAAC TTTTATTCCT
  601 CATGCTCCTG AAATAGATGT CTTGGCATTT AGTACATTCT TTTCCTTGCA CTCCCAACCC
  661 AGAATCCAGC TCCACAGATA CATTGCTACT GTCATCATAA AAAGATCTTG TGGTCCACAG
  721 ATCCTCTAGC CCAGAAATAT GAGTCTCCCA AAGTTCCCTA GCATTTCAAA ATCCAACGTG
  781 CAGCAAACAA TGTGGAATTC CAATAACCCC CCACTCCTTG TTCTCCAGAC CTGTGCACTC
  841 TATCTGTGCA ACAGAGATGC CTGCTGACCT GCCCTGCCAC TAGTGCATGC ATATGTGAAG
  901 CTTAGAGCTC GAGATCTTAA TCATTACCCT GTTATCCCTA TTTAAATGAC CTGCAGGCAT
  961 GCAAGCTTGG CACTGGCCGT CGTTTTACAA CGTCGTGACT GGGAAAACCC TGGCGTTACC
 1021 CAACTTTAAT CGCTTGCAGC ACATTCCCCT TTCGCAGCCT GGCCGTAATA GCGAAGAGGC
1081 TGCAACGAAT CGCCTTCCTA ACAAGGTTGG CGCAGACT
//
Primer: pAxCALNL_F1
Sequence file: RDB14605_A7B9c.seq check
>05910_14605_A7B9_pAxCALNL_F1_E03_05_ABI08.ab1
    1 ACCATGTTAT CTTATCATGT CTGCTCGAAG CGGCCGCTCT AGAATTACTG CTCGTTCTTC
   61 AGCACGCGCT CCACGAAGCT CTTGATGTAC TTACCCATTT CATCTGGAGC GTCCTCCTGG
  121 CTGAAGTGGA GGCCCTTCAC CTTCACGAAC TCGGTGTTAG GGAACTTCTT AGCTCCCTCG
  181 ACAATAGCGT TGGAAAAGAA CCCAGGGTCG GACTCGATGA ACATCTTAGG CAGATCGTCG
  241 CTGGCCCGAA GGTAGGCGTT GTAGTTGCGG ACAATCTGGA CGACGTCGGG CTTGCCTCCC
  301 TTAACGAGAG GGATCTCGCG AGGCCAGGAG AGGGTAGGCC GTCTAACCTC GCCCTTCTCC
  361 TTGAATGGCT CCAGGTAGGC AGCGAACTCC TCAGGCTCCA GTTTCCGCAT GATCTTGCTT
  421 GGGAGCATGG TCTCGACGAA GAAGTTATTC TCAAGCACCA TTTTCTCGCC CTCTTCGCTC
  481 TTGATCAGGG CGATATCCTC CTCGATGTCA GGCCACTCGT CCCAGGACTC GATCACGTCC
  541 ACGACACTCT CAGCATGGAC GATGGCCTTG ATCTTGTCTT GGTGCTCGTA GGAGTAGTGA
  601 AAGGCCAGAC AAGCCCCCCA GTCGTGGCCC ACAAAGATGA TTTTCTTTGG AAGGTTCAGC
  661 AGCTCGAACC AAGCGGTGAG GTACTTGTAG TGATCCAGGA GGCGATATGA GCCATTCCCG
  721 CTCTTGCCGG ACTTACCCAT TCCGATCAGA TCAGGGATGA TGCATCTAGC CACGGGCTCG
  781 ATGTGAGGCA CGACGTGCCT CCACAGGTAG CTGGAGGCAG CGTTACCATG CAGAAAAATC
  841 ACGGCGTTCT CGGCGTGCTT CTCGGAATCA TAGTAGTTGA TGAAGGAGTC CAGCACGTTC
  901 ATTTGCTTGC AGCGAGCCCA CCACTGAGGC CCAGTGATCA TGCGTTTGCG TTGCTCGGGG
  961 TCGTACACCC TTGGAAGCCA TGGGTGGCTA GCCTATAGTG AGTCGTATTA AGTACTCTAG
 1021 CCTTAGAGGC TGGTATTTGG ACCTGGGAGT GACACCTGGT GCAGAAAGCA AGTGGAATGT
1081 CAGTAGACCA ATTAG
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles